EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525808-94-00

Enrollment

Registered

2026-07-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncology

Brief summary

Phase Ib: Dose-Limiting Toxicity (DLT) according to CTCAE version 5.0., Phase Ib: Recommended Phase 2 Dose (RP2D)., Phase ll: Objective Response Rate (ORR) according to RECIST criteria version 1.1.

Detailed description

Progression-Free Survival (PFS), Overall Survival (OS), Duration of Response (DoR)

Interventions

DRUGLP-184

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Phase Ib: Dose-Limiting Toxicity (DLT) according to CTCAE version 5.0., Phase Ib: Recommended Phase 2 Dose (RP2D)., Phase ll: Objective Response Rate (ORR) according to RECIST criteria version 1.1.	—

Secondary

Measure	Time frame
Progression-Free Survival (PFS), Overall Survival (OS), Duration of Response (DoR)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 11, 2026